However, given that the core principle of CRISPR/Cas9 was to knock out the target sequence, the MSH2 gene screened by Andrew et al. was actually a gene that mediated bladder cancer to be more sensitive to cisplatin, rather than a drug-resistant gene. The gene discussed is MSH2; the disease is urinary bladder carcinoma.